ArticleAnnals of medicine2025

First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis.

Si-Jun Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.